Gustavsson Heléne, Jennbacken Karin, Welén Karin, Damber Jan-Erik
Department of Urology, Lundberg Laboratory for Cancer Research, Institute of Clinical Sciences, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden.
Prostate. 2008 Feb 1;68(2):161-70. doi: 10.1002/pros.20672.
The aim of this study was to investigate how the expression of genes regulating angiogenesis is altered when prostate cancer cells progress into androgen-independency.
A gene array specific for angiogenesis was used to compare the human prostate cancer cell line LNCaP (androgen-dependent) with its more angiogenic and tumorigenic subline LNCaP-19 (androgen-independent). Results were verified with real-time RT-PCR, and further investigations were focused on the angiogenesis inhibitor a disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1). Expression of ADAMTS1 was investigated in vitro as well as in subcutaneous tumors with real-time RT-PCR and Western blotting. Microvessel density (MVD), versican proteolysis and protein levels of TIMP-2 and TIMP-3, known as ADAMTS1 inhibitors, were also analyzed in tumor xenografts.
The gene array revealed decreased expression of ADAMTS1, ephrin-A5, fibronectin 1, and neuropilin 1 in LNCaP-19 compared to LNCaP, while expression of midkine and VEGF were increased. Further studies showed that mRNA and protein levels of ADAMTS1 were significantly lower in LNCaP-19 compared to LNCaP, both in vitro and in subcutaneous tumors. The amount of ADAMTS1 correlated negatively with MVD, but no relation was found between ADAMTS1 and versican proteolysis.
Expression of several genes associated with angiogenesis was altered during transition into androgen-independency. Among these, a significant decrease was found for ADAMTS1, whose expression inversely correlated with MVD. Its role in progression of prostate cancer needs further investigation, but this inhibitor of angiogenesis could be an interesting candidate for future anti-angiogenic therapy.
本研究旨在探究当前列腺癌细胞发展为雄激素非依赖型时,调节血管生成的基因表达是如何改变的。
使用一种针对血管生成的基因芯片,将人前列腺癌细胞系LNCaP(雄激素依赖型)与其血管生成能力更强且致瘤性更高的亚系LNCaP-19(雄激素非依赖型)进行比较。结果通过实时逆转录聚合酶链反应(RT-PCR)进行验证,进一步的研究聚焦于血管生成抑制剂含血小板反应蛋白基序的解聚素和金属蛋白酶1(ADAMTS1)。采用实时RT-PCR和蛋白质免疫印迹法在体外以及皮下肿瘤中研究ADAMTS1的表达。还在肿瘤异种移植模型中分析了微血管密度(MVD)、多功能蛋白聚糖的蛋白水解作用以及已知为ADAMTS1抑制剂的金属蛋白酶组织抑制因子2(TIMP-2)和金属蛋白酶组织抑制因子3(TIMP-3)的蛋白水平。
基因芯片显示,与LNCaP相比,LNCaP-19中ADAMTS1、 Ephrin-A5、纤连蛋白1和神经纤毛蛋白1的表达降低,而中期因子和血管内皮生长因子(VEGF)的表达增加。进一步研究表明,无论是在体外还是皮下肿瘤中,LNCaP-19中ADAMTS1的mRNA和蛋白水平均显著低于LNCaP。ADAMTS1的量与MVD呈负相关,但未发现ADAMTS1与多功能蛋白聚糖的蛋白水解作用之间存在关联。
在向雄激素非依赖型转变过程中,几种与血管生成相关的基因表达发生了改变。其中,ADAMTS1显著降低,其表达与MVD呈负相关。其在前列腺癌进展中的作用需要进一步研究,但这种血管生成抑制剂可能是未来抗血管生成治疗的一个有吸引力的候选药物。